Search

Your search keyword '"Rubin de Celix C"' showing total 4 results
Start Over Author "Rubin de Celix C"
4 results on '"Rubin de Celix C"'

1. P523 Effectiveness of biological treatments for inflammatory bowel disease in the elderly patients

Author

Suarez Ferrer, C J, primary, Mesonero, F, additional, Caballol, B, additional, Ballester, M P, additional, Baston Rey, I, additional, Castaño Garcia, A, additional, Miranda Bautista, J, additional, Saiz Chumillas, R, additional, Benitez, J M, additional, Sanchez Delgado, L, additional, Lopez-Garcia, A, additional, Rubin de Celix, C, additional, Martin-Arranz, M D, additional, Lopez Sanroman, A, additional, Fernandez-Clotet, A, additional, Merino Murgui, V, additional, Calviño Suarez, C, additional, Florez, P, additional, Lobato Matilla, M E, additional, Sicilia, B, additional, Soto Escribano, P, additional, Maroto Martin, C, additional, Alonso Abreu, I, additional, Melcarne, L, additional, Elena, P G, additional, Iyo, E, additional, Elosua Gonzalez, A, additional, Saiz, E, additional, Hernandez Villalba, L, additional, Perez Galindo, P, additional, Torrealba Medina, L, additional, Monsalve Alonso, S, additional, Olmos Jerez, J A, additional, Dueñas Sadornil, C, additional, and Barreiro-De Acosta, M, additional

Published
2022
Full Text
View/download PDF

2. P410 Safety of biological drugs for inflammatory bowel disease in elderly patients

Author

Suarez Ferrer, C J, primary, Mesonero, F, additional, Caballol, B, additional, Ballester, M P, additional, Baston Rey, I, additional, Castaño Garcia, A, additional, Miranda Bautista, J, additional, Saiz Chumillas, R, additional, Benitez, J M, additional, Sanchez Delgado, L, additional, Lopez-Garcia, A, additional, Rubin de Celix, C, additional, Lopez Sanroma, A, additional, Martin-Arranz, M D, additional, Fernández-Clotet, A, additional, Merino Murgui, V, additional, Calviño Suárez, C, additional, Florez, P, additional, Lobato matilla, M E, additional, Sicilia, B, additional, Soto Escribano, P, additional, Maroto Martin, C, additional, Alonso Abreu, I, additional, Melcarne, L, additional, Plaza Santos, R, additional, Marques Cami, M, additional, Caballero Mateos, A, additional, Gómez Díez, C, additional, Calafat, M, additional, Alonso Galan, H, additional, Vega Villaamil, P, additional, Castro Senosiain, B, additional, Guerro Moya, A, additional, Rodriguez Diaz, C Y, additional, Spicakova, K, additional, Manceñido Marcos, N, additional, Molina, G, additional, De Castro, L, additional, Mañosa Ciria, M, additional, and Barreiro-De Acosta, M, additional

Published
2022
Full Text
View/download PDF

3. P338 effectiveness and safety of biological therapies in elderly inflammatory bowel diseases patients results from a multi center study of Geteccu

Author

Suarez Ferrer, C J, primary, Mesonero, F, additional, Caballol, B, additional, Saiz Chumillas, R, additional, Bastón-Rey, I, additional, Rubin de Celix, C, additional, Melcarne, L, additional, Caballero Mateos, A, additional, Calafat, M, additional, Alonso Galan, H, additional, Vega Villaamil, P, additional, Castro Senosiain, B, additional, Rodriguez Diaz, C Y, additional, Plaza Santos, R, additional, Marques Cami, M, additional, Rodriguez Grau, M C, additional, Ramirez, F, additional, Lopez-García, A, additional, Gomez Pastrana, B, additional, Gonzalez Partida, I, additional, Botella Mateu, B, additional, Cuevas del Campo, L, additional, Gonzalez Peña, E, additional, Iyo, E, additional, Elosua Gonzalez, A, additional, Sainz, E, additional, Hernandez, L, additional, Perez Galindo, P, additional, Rueda Garcia, J L, additional, Martin-Arranz, M D, additional, Lopez Sanroman, A, additional, Fernandez-Clotet, A, additional, Sicilia, B, additional, Calviño Suárez, C, additional, Mañosa Ciria, M, additional, and Barreiro-De Acosta, M, additional

Published
2021
Full Text
View/download PDF

4. Efficacy and safety of biological treatment for inflammatory bowel disease in elderly patients: Results from a GETECCU cohort.

Author

Suárez Ferrer C, Mesonero Gismero F, Caballol B, Ballester MP, Bastón Rey I, Castaño García A, Miranda Bautista J, Saiz Chumillas R, Benitez JM, Sanchez-Delgado L, López-García A, Rubin de Celix C, Alonso Abreu I, Melcarne L, Plaza Santos R, Marques-Camí M, Caballero Mateos A, Gómez Díez C, Calafat M, Galan HA, Vega Vilaamil P, Castro Senosiain B, Guerro Moya A, Rodriguez Diaz CY, Spicakova K, Manceñido Marcos N, Molina G, de Castro Parga L, Rodriguez Angulo A, Cuevas Del Campo L, Rodriguez Grau MDC, Ramirez F, Gomez Pastrana B, Gonzalez Partida I, Botella Mateu B, Peña Gonzalez E, Iyo E, Elosua Gonzalez A, Sainz Arnau E, Hernandez Villalba L, Perez Galindo P, Torrealba Medina L, Monsalve Alonso S, Olmos Perez JA, Dueñas Sadornil C, Garcia Ramirez L, Martín-Arranz MD, López Sanroman A, Fernández A, Merino Murgui V, Calviño Suárez C, Flórez-Diez P, Lobato Matilla ME, Sicilia B, Soto Escribano P, Maroto Martin C, Mañosa M, and Barreiro-De Acosta M

Subjects
Humans, Aged, Male, Female, Retrospective Studies, Treatment Outcome, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal adverse effects, Aged, 80 and over, Adalimumab therapeutic use, Adalimumab adverse effects, Ustekinumab therapeutic use, Ustekinumab adverse effects, Antibodies, Monoclonal, Humanized therapeutic use, Antibodies, Monoclonal, Humanized adverse effects, Biological Therapy adverse effects, Remission Induction, Inflammatory Bowel Diseases drug therapy
Abstract

Introduction: Biological therapies used for the treatment of inflammatory bowel disease (IBD) have shown to be effective and safe, although these results were obtained from studies involving mostly a young population, who are generally included in clinical trials. The aim of our study was to determine the efficacy and safety of the different biological treatments in the elderly population., Methods: Multicenter study was carried out in the GETECCU group. Patients diagnosed with IBD and aged over 65 years at the time of initiating biological therapy (infliximab, adalimumab, golimumab, ustekinumab or vedolizumab) were retrospectively included. Among the patients included, clinical response was assessed after drug induction (12 weeks of treatment) and at 52 weeks. Patients' colonoscopy data in week 52 were assessment, where available. Regarding complications, development of oncological events during follow-up and infectious processes occurring during biological treatment were collected (excluding bowel infection by cytomegalovirus)., Results: A total of 1090 patients were included. After induction, at approximately 12-14 weeks of treatment, 419 patients (39.6%) were in clinical remission, 502 patients (47.4%) had responded without remission and 137 patients (12.9%) had no response. At 52 weeks of treatment 442 patients (57.1%) had achieved clinical remission, 249 patients had responded without remission (32.2%) and 53 patients had no response to the treatment (6.8%). Before 52 weeks, 129 patients (14.8%) had discontinued treatment due to inefficacy, this being significantly higher (p<0.0001) for Golimumab - 9 patients (37.5%) - compared to the other biological treatments analyzed. With respect to tumor development, an oncological event was observed in 74 patients (6.9%): 30 patients (8%) on infliximab, 23 (7.14%) on adalimumab, 3 (11.1%) on golimumab, 10 (6.4%) on ustekinumab, and 8 (3.8%) on vedolizumab. The incidence was significantly lower (p=0.04) for the vedolizumab group compared to other treatments. As regards infections, these occurred in 160 patients during treatment (14.9%), with no differences between the different biologicals used (p=0.61): 61 patients (19.4%) on infliximab, 39 (12.5%) on adalimumab, 5 (17.8%) on golimumab, 22 (14.1%) on ustekinumab, and 34 (16.5%) on vedolizumab., Conclusions: Biological drug therapies have response rates in elderly patients similar to those described in the general population, Golimumab was the drug that was discontinued most frequently due to inefficacy. In our experience, tumor development was more frequent in patients who used anti-TNF therapies compared to other targets, although its incidence was generally low and that this is in line with younger patients based on previous literature., (Copyright © 2024 Elsevier España, S.L.U. All rights reserved.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results